Generics Stocks
Off-patent pharmaceutical producers and wholesale distributors operate in a high-volume, low-margin environment defined by patent expiration cycles and aggressive price erosion. Success depends on manufacturing scale, supply chain vertical integration, and the ability to navigate complex FDA Abbreviated New Drug Applications to capture first-to-market exclusivity periods.
As of Oct 23, 2026, Generics has 13 US-listed companies worth $503B combined. The median member moved -2.3% over the past week; AMRX led at +6.3% and SBFM trailed at -32.4%.
Companies in Generics
- NVS – Novartis AG ADR, $287B
- COR – Cencora Inc., $65B
- CAH – Cardinal Health Inc, $59.2B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- VTRS – Viatris Inc, $21.2B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, $7.1B
- OGN – Organon & Co, $3.6B
- ANIP – ANI Pharmaceuticals Inc, $1.7B
- AMPH – Amphastar P, $1.1B
- CPHI – China Pharma Holdings Inc, $30.5M
- SBFM – Sunshine Biopharma Inc, $3.3M
- LIPO – Lipella Pharmaceuticals Inc. Common Stock, $2,310